ASCENT
The trial that proved a TROP2 ADC could nearly double survival in heavily pretreated triple-negative breast cancer.
529 patients, ≥2 prior lines. PFS 5.6 vs 1.7 months; OS 12.1 vs 6.7 months (HR 0.48). Benefit regardless of TROP2 expression level, a finding that shaped the field's view that IHC selection is unnecessary for TROP2 ADCs.
- Median 5.6 vs 1.7 months with Sacituzumab govitecan compared with Chemotherapy (TPC); about 3.9 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 59 percent lower chance of the event at any given time (hazard ratio 0.41, likely range 0.32 to 0.52).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- Median 12.1 vs 6.7 months with Sacituzumab govitecan compared with Chemotherapy (TPC); about 5.4 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 52 percent lower chance of the event at any given time (hazard ratio 0.48, likely range 0.38 to 0.59).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- 35 vs 5 out of 100 had their tumour shrink with Sacituzumab govitecan compared with Chemotherapy (TPC); 30 more per 100.
- Roughly one extra person helped for every 3 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- These results apply to the people the trial enrolled: Pretreated metastatic TNBC: sacituzumab govitecan vs chemotherapy. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
529 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (patients without brain metastases)primary | Sacituzumab govitecan | 235 | 5.6 months | 0.41 (0.32–0.52) | <0.001 | link |
| Chemotherapy (TPC) | 233 | 1.7 months | ||||
| Overall survival | Sacituzumab govitecan | — | 12.1 months | 0.48 (0.38–0.59) | <0.001 | link |
| Chemotherapy (TPC) | — | 6.7 months | ||||
| Objective response rate | Sacituzumab govitecan | — | 35% | — | — | link |
| Chemotherapy (TPC) | — | 5% |
Pages like this
not linked directly; found by shared links- TrialASCENT-03
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Sacituzumab govitecan.
- TrialASCENT-04 / KEYNOTE-D19
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Sacituzumab govitecan.
- TrialTROPION-Breast02
Shares TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Triple-negative breast cancer (TNBC).
- IdeaTROP2 PET to choose and sequence TROP2 ADCs
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Sacituzumab govitecan, TROP2.
- TrialTROPION-Breast05
Shares TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Triple-negative breast cancer (TNBC).
- PairingTROP2 PET → TROP2 ADC selection
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Sacituzumab govitecan, TROP2, Triple-negative breast cancer (TNBC).
- PersonHope S. Rugo
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, Sacituzumab govitecan, TROP2, Triple-negative breast cancer (TNBC).
- TrialTROPiCS-02
Shares Sacituzumab govitecan, TROP2.